Projectes

IrsiCaixa compta amb un centenar de projectes de recerca nacionals i internacionals actius cada any, finançats tant per entitats públiques com privades.

Paraules clau

Grup de recerca

Investigador/a

Des del

Fins el

RBD Dimer recombinant protein vaccine against SARS-CoV-2

Estatus del projecte

Vigent

Inici/Fi

2021

/

2024

Investigador/a principal

Marta Ruiz Riol

Julià Blanco Arbués

Christian Brander

Jorge Carrillo Molina

Samandhy Cedeño Briceño

Julia García Prado

Nuria Izquierdo Useros

Tuixent Escribà Bel

Eulalia Grau Segú

Beatriz Mothe Pujadas

Personal investigador extern

Èlia Torroella

Línia estratègica

Càncer

Malalties infeccioses emergents

Entitat finançadora

European Commission

Codi: 101046118
Incorporation of a new subject and new groups to the Consortium of the Centro de Investigación Biomédica en Red M.P. (CIBER)

Estatus del projecte

Vigent

Inici/Fi

2022

Investigador/a principal

Julia García Prado

Javier Martínez-Picado

Entitats participants

IrsiCaixa, IGTP

Entitat finançadora

ISCIII
Novel bispecific Trimerbody targeting human 4-1BB and Env for immunotherapy based HIV-1 curative therapeutics

Estatus del projecte

Vigent

Inici/Fi

2020

/

2022

Investigador/a principal

Julia García Prado

Entitats participants

IrsiCaixa, Hospital 12 de Octubre research institute
Identification and characterization of T cell protective responses against CoV2. ISCIII COV20/0660

Estatus del projecte

Vigent

Inici/Fi

2021

/

2022

Investigador/a principal

Julia García Prado

Entitat finançadora

Instituto de Salud Carlos III (ISCIII)
SARS-CoV-2 infection among healthcare professionals: demographic characteristics and serological and immune responses related to progression's phenotype

Estatus del projecte

Vigent

Inici/Fi

2021

/

2022

Personal investigador extern

Concepció Violán Fors

Entitats participants

Irsicaixa / IGTP/ HUGTIP/ IDIAPJGol

Entitat finançadora

Direcció General de Recerca i Innovació en Salut
Enhancing Tissue-Specific Immune Microenvironments for the Cure of HIV. ETI-CURE “La Caixa” Health Research HR20-00218

Estatus del projecte

Vigent

Inici/Fi

2021

/

2024

Investigador/a principal

Julia García Prado

Personal investigador extern

Maria José Buzón

Entitats participants

Irsicaixa / VHIR / Universidad Autónoma de Madrid

Entitat finançadora

ETI-CURE “La Caixa” Health Research
DURVAST: A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors

Estatus del projecte

Vigent

Inici/Fi

2017

/

2019

Investigador/a principal

Javier Martínez-Picado

Entitats participants

Spanish Lung Cancer Cooperative Group & IrsiCaixa AIDS Research Institute.

Entitat finançadora

AstraZeneca
Translational study of Inhibitory Receptors in HIV-1 infection: Identification of novel immunotherapeutic targets to reverse T-cell immune exhaustion

Estatus del projecte

Vigent

Inici/Fi

2018

/

2020

Investigador/a principal

Julia García Prado

Entitats participants

Institut de Recerca de la Sida IrsiCaixa

Entitat finançadora

Ministry of the Economy, Industry and Competitiveness - Carlos III Health Institute (ISCIII) – FEDER. PI17/00164
Preclinical evaluation of immunoregulatory molecules in combination with latency reactivators for the development of new HIV-1 erradication strategies

Estatus del projecte

Vigent

Inici/Fi

2015

/

2018

Investigador/a principal

Julia García Prado

Entitat finançadora

Ministry of the Economy and Competitiveness - Carlos III Health Institute (ISCIII) - FEDER. PI14/01058
LKR155762 Combine use of vaccines an immune check blockers to boost CTL activity against the reservoir

Estatus del projecte

Vigent

Inici/Fi

2017

/

2019

Investigador/a principal

Julia García Prado

Entitat finançadora

MSD